Reckitt Benckiser (Australia) Pty Ltd v AFT Pharmaceuticals (AU) Pty Ltd

Link copied
Case Copied 1 min read

RECKITT BENCKISER (AUSTRALIA) PTY LTD

v

AFT PHARMACEUTICALS (AU) PTY LTD

[2022] HCASL 70
S1/2022

  1. This application for special leave to appeal from a judgment of the Full Court of the Federal Court of Australia (Nicholas, Markovic and Burley JJ) raises no issue of general principle sufficient to warrant the grant of special leave to appeal. The application should be dismissed.

  2. Pursuant to r 41.08.1 of the High Court Rules 2004 (Cth), we direct the Registrar to draw up, sign and seal an order dismissing the application with costs.

M.M. Gordon J.J. Edelman
7 April 2022
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Reckitt Benckiser (Australia) Pty Ltd v AFT Pharmaceuticals... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2022] HCASL 70
Decision Date

CaseChat Overview and Summary

Reckitt Benckiser (Australia) Pty Ltd applied for special leave to appeal against a decision of the Full Court of the Federal Court of Australia in a case involving a dispute over patent rights and alleged infringement. The Full Court had found that AFT Pharmaceuticals (AU) Pty Ltd had not infringed Reckitt Benckiser's patent for a pharmaceutical composition. The Full Court dismissed Reckitt Benckiser's appeal against a primary judge's decision, which had ruled that the patent was invalid. The primary judge found that the patent was not new or useful and therefore not patentable. Reckitt Benckiser argued that the Full Court had erred in finding that the patent was invalid and that the Full Court had failed to properly consider certain evidence.

The legal issues in the case included whether the patent was valid and whether AFT Pharmaceuticals had infringed the patent. The High Court was asked to consider whether the Full Court had erred in finding that the patent was invalid and whether the Full Court had properly considered the evidence. The High Court also considered whether the case raised an issue of general principle sufficient to warrant the grant of special leave to appeal.

The High Court held that the case did not raise an issue of general principle sufficient to warrant the grant of special leave to appeal. The court found that the Full Court had properly considered the evidence and had not erred in finding that the patent was invalid. The court also found that the Full Court had properly considered whether AFT Pharmaceuticals had infringed the patent. The High Court held that the application for special leave to appeal should be dismissed with costs.

The High Court's decision in this case reinforces the importance of properly considering evidence in patent cases and the need for patents to meet the requirements of novelty and usefulness. The court's decision also highlights the limited circumstances in which special leave to appeal will be granted to the High Court.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established